Science & Innovation

Presentations & Publications

July 30, 2023

Suprachoroidal Delivery of Investigational ABBV-RGX-314 for Neovascular AMD: Results from the Phase II AAVIATE® Study

David Boyer, MD
Adjunct Clinical Professor Ophthalmology Keck School of Medicine Partner Retina Vitreous Associates Medical Group
February 24, 2023

RGX-111 Gene Therapy For The Treatment Of Severe Mucopolysaccharidosis Type I (MPS I): Interim Analysis Of Data From The First In Human Study

Raymond Wang, M.D., Division of Metabolic Disorders, CHOC Children's Hospital, Department of Pediatrics, University of California, Irvine, CA
February 22, 2023

RGX-121 Gene Therapy For The Treatment Of Neuronopathic Mucopolysaccharidosis Type II (MPS II): Interim Analysis Of Data From The First In Human Study (Abstract #LB-21)

Can Ficicioglu, M.D., Ph.D., Professor of Pediatrics at Perelman School of Medicine at the University of Pennsylvania, Director of the Newborn Metabolic Screening Program and the Lysosomal Storage Diseases Program, Clinical Director of the Metabolic Disease Program Children's Hospital of Philadelphia
February 11, 2023

Subretinal Delivery Of RGX-314 For Neovascular AMD: A Phase II Pharmacodynamic Study

Charles C. Wykoff MD, PhD, Director of Research at Retina Consultants of Texas; Chairman of Research, Retina Consultants of America; and Deputy Chair of Ophthalmology for the Blanton Eye Institute, Houston Methodist Hospital
November 02, 2022

Suprachoroidal Delivery Of RGX-314 For Diabetic Retinopathy Without CI-DME: The Phase II ALTITUDE® Study

Lejla Vajzovic, MD, FASRS, Associate Professor of Ophthalmology and Director of Duke Vitreoretinal Fellowship Program, Vitreoretinal Surgery and Disease, Department of Ophthalmology, Duke University School of Medicine
October 01, 2022

Gene Therapy For Neovascular AMD: Subretinal RGX-314: Phase I/IIa Long-Term Follow-Up Results Up To 4 Years

Peter Campochiaro M.D., Director, Retinal Cell and Molecular Laboratory, Professor of Ophthalmology, The Wilmer Eye Institute, Johns Hopkins University School of Medicine
August 31, 2022

RGX 121 Gene Therapy For The Treatment Of Severe Mucopolysaccharidosis Type II: CAMPSIITE™ Phase I/II/III: A Clinical Study Update

Roberto Giugliani, M.D., Ph.D., Professor, Department of Genetics, UFRGS, Medical Genetics Service, HCPA, Porto Alegre, Brazil
February 12, 2022

Suprachoroidal Delivery Of RGX-314 For Diabetic Retinopathy Without CI-DME: Results From The Phase II ALTITUDE™ Study

Michael Klufas, M.D., Retina Service, Wills Eye Hospital, Assistant Professor of Ophthalmology, Thomas Jefferson University
February 09, 2022

RGX-111 Gene Therapy For The Treatment Of Severe Mucopolysaccharidosis Type I (MPS I): Interim Analysis Of Data From The First In Human Study

Raymond Wang, M.D., Division of Metabolic Disorders, CHOC Children's Hospital, Department of Pediatrics, University of California, Irvine, CA
February 09, 2022

RGX-121 Gene Therapy For The Treatment Of Severe Mucopolysaccharidosis Type II (MPS II): Interim Analysis Of Data From The First In Human Study

Roberto Giugliani, M.D., Ph.D., Presenter title: Professor, Department of Genetics, UFRGS, Medical Genetics Service, HCPA, Porto Alegre, Brazil
November 12, 2021

Two Year Results From The Subretinal RGX-314 Gene Therapy Phase 1/2a Study For The Treatment Of NAMD, And An Update On Suprachoroidal Trials

Robert L. Avery, M.D., Founder of California Retina Consultants and Research Foundation
October 01, 2021

Suprachoroidal Delivery Of RGX-314 For Neovascular AMD: Initial Results From The Phase II AAVIATE® Study

Nikolas London, M.D., M.S., M.S., F.A.C.S., Partner and Director of Research, Retina Consultants of San Diego, Chief of Ophthalmology, Scripps Memorial Hospital
October 01, 2021

Subretinal Delivery Of RGX-314 For Neovascular AMD: End Of Phase I/IIa Study Results

Allen Ho, M.D., Director of Retina Research at Wills Eye Hospital and Mid Atlantic Retina
February 08, 2021

RGX-121 Gene Therapy For Severe Mucopolysaccharidosis Type II (MPS II): Interim Results Of An Ongoing First In Human Trial

Marie-Laure N̩voret, MD РSenior Clinical Development Lead, REGENXBIO
 
October 11, 2019

Key Takeaways From The RGX-314 Phase I/IIa Clinical Trial For Wet AMD (Cohorts 1-5)

Jeffrey Heier, MD – Ophthalmic Consultants of Boston
May 15, 2018

AAV8-AntiVEGFfab Ocular Gene Transfer For Neovascular Age-Related MacularDegeneration

Yuanyuan Liu5, Seth D. Fortmann, Jikui Shen, Erik Wielechowski, Anna Tretiakova, Stephen Yoo, Karen Kozarsky, Jiangxia Wang, James M. Wilson, Peter A. Campochiaro'
December 22, 2011

Adenovirus-Associated Virus Vector–Mediated Gene Transfer In Hemophilia B

The New England Journal of Medicine